By Catherine Eckford2023-11-13T16:53:31
If approved, momelotinib will be the first treatment in the EU indicated for myelofibrosis patients with moderate to severe anaemia.
Already a member? Sign-in
European Pharmaceutical Review delivers authoritative insights, cutting-edge innovations, and expert perspectives that not only inform decisions but drive measurable progress across quality, compliance, and operational excellence.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-05-29T10:14:00Z
2026-04-30T10:37:00
Sponsored by Shimadzu
2026-03-27T15:37:00
Sponsored by IMA Pharma
2025-09-24T15:24:00
Sponsored by Lonza
2026-03-04T15:00:00 2026-03-04T16:00:00
Sponsored by METTLER TOLEDO
2025-09-17T08:00:00
Sponsored by Mastercontrol
2025-09-19T15:46:00
Sponsored by ACCI, By European Pharmaceutical Review
Site powered by Webvision Cloud